...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Due Dilligence
Annual General Meeting Presentation 6/22/2021
See also imtesty's rough transcript here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/762730-reposting-with-link-included/messages/2320824#message
Posted by:
BearDownAZ
on
Jun 23, 2021 09:13AM
May 12, 2021: PBA à Noon Presentation with Resverlogix Corp.
See also imtesty's rough transcript here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/760671-rough-transcript-rvx-21-05-12-pba-at-noon/messages/2315891#message
Posted by:
BearDownAZ
on
May 18, 2021 10:42AM
Resverlogix Corp. Links
NEJM BETonMACE Publication - Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes A Randomized Clinical Trial
Posted by:
BearDownAZ
on
Mar 31, 2020 08:20AM
The BET Protein Inhibitor Apabetalone Reduces Congestive Heart Failure Incidence in Patients with Acute Coronary Syndrome and Diabetes: Results from the BETonMACE Trial - ACC/WCC 2020 Poster
Posted by:
BearDownAZ
on
Mar 31, 2020 08:18AM
Epigenetic Reader Inhibitor Apabetalone (RVX-208) Counters Proinflammatory Hyperactivation of CD14+ Monocytes from Patients with Type 2 Diabetes and Cardiovascular Disease - ACC/WCC 2020 Poster
Posted by:
BearDownAZ
on
Mar 31, 2020 08:18AM
Epigenetics in CVD: A collection of PACE-CME symposium presentations
Posted by:
BearDownAZ
on
Feb 11, 2020 10:52AM
Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
Posted by:
BearDownAZ
on
Dec 10, 2019 09:16PM
Epigenetic Modulator Apabetalone Inhibits Monocyte Adhesion To Brain Endothelial Cells By Downregulating Key Neuroinflammation Markers In Vitro And In Vivo - CTAD 2019 Poster
Posted by:
BearDownAZ
on
Dec 08, 2019 02:30PM
BETonMACE Cognitive Assessment Results Corporate Webcast Slides
Posted by:
BearDownAZ
on
Dec 06, 2019 07:41PM